CCM
BMRN icon

Cinctive Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Cinctive Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-28,736
Closed -$2.03M – 377
2025
Q1 		$2.03M Buy
+28,736
New +$1.93M 0.16% 158
2024
Q3 		– Sell
-43,926
Closed -$3.62M – 391
2024
Q2 		$3.62M Buy
43,926
+2,440
+6% +$203K 0.17% 184
2024
Q1 		$3.62M Buy
41,486
+3,986
+11% +$357K 0.17% 163
2023
Q4 		$3.62M Buy
+37,500
New +$3.32M 0.24% 130

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cinctive Capital Management's BMRN Position: Q2 2025 in Review

Cinctive Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2025, closing a stake of 28,736 shares — an estimated $2.03M sold.

Cinctive Capital Management first reported a position in BMRN in Q4 2023 and held it in 4 quarters. The position peaked at $3.62M in Q1 2024. 581 funds tracked by Wall St. Rank hold BMRN as of Q2 2025.

  • Cinctive Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Cinctive Capital Management sold 28,736 BioMarin Pharmaceuticals shares in Q2 2025, an estimated $2.03M.
  • Cinctive Capital Management first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 4 quarters.
  • Cinctive Capital Management's BioMarin Pharmaceuticals position peaked at $3.62M in Q1 2024.
  • 581 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2025.

Based on Cinctive Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.